U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
Go back to U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children| Pfizer Inc. (NYSE: PFE) | Delayed: 24.04 -0.68 (2.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.72 | 52 Week High | $37.39 | |||
| Open | $24.80 | 52 Week Low | $28.25 | |||
| Day High | $25.11 | P/E | 14.57 | |||
| Day Low | $23.93 | EPS | $1.65 | |||
| Volume | 76,926,336 | |||||
